JP2020510698A - 個別化された免疫原性ペプチドの同定のプラットフォーム - Google Patents

個別化された免疫原性ペプチドの同定のプラットフォーム Download PDF

Info

Publication number
JP2020510698A
JP2020510698A JP2019568815A JP2019568815A JP2020510698A JP 2020510698 A JP2020510698 A JP 2020510698A JP 2019568815 A JP2019568815 A JP 2019568815A JP 2019568815 A JP2019568815 A JP 2019568815A JP 2020510698 A JP2020510698 A JP 2020510698A
Authority
JP
Japan
Prior art keywords
subject
polypeptide
amino acid
hla class
binding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019568815A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020510698A5 (cg-RX-API-DMAC7.html
Inventor
リシエヴィッチ、ジュリアナ
モルナー、レヴェンテ
トゥケ、エニク、アール．
トート、ヨージェフ
ロリンツ、オルショヤ
シゾヴスキー、ゾルト
ソモギー、エステル
パンヤ、カタリン
メジェシ、モニカ
Original Assignee
トレオス バイオ ゼットアールティー
トレオス バイオ ゼットアールティー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=61386864&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP2020510698(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from EP17159242.1A external-priority patent/EP3369431A1/en
Priority claimed from EP17159243.9A external-priority patent/EP3370065A1/en
Priority claimed from GBGB1703809.2A external-priority patent/GB201703809D0/en
Application filed by トレオス バイオ ゼットアールティー, トレオス バイオ ゼットアールティー filed Critical トレオス バイオ ゼットアールティー
Publication of JP2020510698A publication Critical patent/JP2020510698A/ja
Publication of JP2020510698A5 publication Critical patent/JP2020510698A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0002—Fungal antigens, e.g. Trichophyton, Aspergillus, Candida
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4238—Regulators of development
    • A61K40/424—Apoptosis related proteins, e.g. survivin or livin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4242—Transcription factors, e.g. SOX or c-MYC
    • A61K40/4243—Wilms tumor 1 [WT1]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4267—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K40/4268—MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4267—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K40/4269—NY-ESO
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4267—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K40/427—PRAME
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6869—Methods for sequencing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56977—HLA or MHC typing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/575—
    • G01N33/5758—
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B15/00—ICT specially adapted for analysing two-dimensional or three-dimensional molecular structures, e.g. structural or functional relations or structure alignment
    • G16B15/30—Drug targeting using structural data; Docking or binding prediction
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55544—Bacterial toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55588—Adjuvants of undefined constitution
    • A61K2039/55594—Adjuvants of undefined constitution from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/605—MHC molecules or ligands thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6075—Viral proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/812—Breast
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/82—Colon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/892—Reproductive system [uterus, ovaries, cervix, testes]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/49—Breast
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/50—Colon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/59—Reproductive system, e.g. uterus, ovaries, cervix or testes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Oncology (AREA)
  • Zoology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Medical Informatics (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
JP2019568815A 2017-03-03 2018-03-02 個別化された免疫原性ペプチドの同定のプラットフォーム Pending JP2020510698A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
EP17159242.1 2017-03-03
EP17159243.9 2017-03-03
EP17159242.1A EP3369431A1 (en) 2017-03-03 2017-03-03 Vaccine
EP17159243.9A EP3370065A1 (en) 2017-03-03 2017-03-03 Immunogenic peptides
GB1703809.2 2017-03-09
GBGB1703809.2A GB201703809D0 (en) 2017-03-09 2017-03-09 Vaccine
PCT/EP2018/055231 WO2018158456A1 (en) 2017-03-03 2018-03-02 Personalised immunogenic peptide identification platform

Publications (2)

Publication Number Publication Date
JP2020510698A true JP2020510698A (ja) 2020-04-09
JP2020510698A5 JP2020510698A5 (cg-RX-API-DMAC7.html) 2021-04-15

Family

ID=61386864

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2019568815A Pending JP2020510698A (ja) 2017-03-03 2018-03-02 個別化された免疫原性ペプチドの同定のプラットフォーム
JP2019568816A Active JP7437939B2 (ja) 2017-03-03 2018-03-02 集団に基づいた免疫原性ペプチドの同定のプラットフォーム
JP2019568814A Active JP7751374B2 (ja) 2017-03-03 2018-03-02 ペプチドワクチン
JP2022197534A Pending JP2023051941A (ja) 2017-03-03 2022-12-09 ペプチドワクチン

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2019568816A Active JP7437939B2 (ja) 2017-03-03 2018-03-02 集団に基づいた免疫原性ペプチドの同定のプラットフォーム
JP2019568814A Active JP7751374B2 (ja) 2017-03-03 2018-03-02 ペプチドワクチン
JP2022197534A Pending JP2023051941A (ja) 2017-03-03 2022-12-09 ペプチドワクチン

Country Status (16)

Country Link
US (9) US20180264094A1 (cg-RX-API-DMAC7.html)
EP (3) EP3589310A1 (cg-RX-API-DMAC7.html)
JP (4) JP2020510698A (cg-RX-API-DMAC7.html)
KR (4) KR20240156643A (cg-RX-API-DMAC7.html)
CN (4) CN110651189B (cg-RX-API-DMAC7.html)
AU (3) AU2018228785B2 (cg-RX-API-DMAC7.html)
BR (3) BR112019018312A2 (cg-RX-API-DMAC7.html)
CA (3) CA3054866A1 (cg-RX-API-DMAC7.html)
CL (4) CL2019002533A1 (cg-RX-API-DMAC7.html)
CO (3) CO2019010503A2 (cg-RX-API-DMAC7.html)
IL (3) IL268919B2 (cg-RX-API-DMAC7.html)
MA (3) MA47683A (cg-RX-API-DMAC7.html)
MX (3) MX2019010460A (cg-RX-API-DMAC7.html)
SG (3) SG11201907402SA (cg-RX-API-DMAC7.html)
WO (3) WO2018158456A1 (cg-RX-API-DMAC7.html)
ZA (2) ZA201904723B (cg-RX-API-DMAC7.html)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20210086611A (ko) * 2018-09-04 2021-07-08 트레오스 바이오 리미티드 면역유전적 암 스크리닝 검사
WO2023017768A1 (ja) 2021-08-10 2023-02-16 日本電気株式会社 情報処理システム及び情報処理方法
WO2023058625A1 (ja) 2021-10-04 2023-04-13 日本電気株式会社 管理方法、管理システム及び電子カルテシステム
WO2024038510A1 (ja) 2022-08-17 2024-02-22 日本電気株式会社 情報処理システム、情報処理方法及びプログラム

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112017020058A2 (pt) * 2015-03-20 2018-06-05 Childrens Nat Medical Ct processo para produzir uma célula-t específica, composição, banco de células-t específicas, método de tratamento, e, banco ou instalação de armazenamento de células.
KR20240156643A (ko) 2017-03-03 2024-10-30 트레오스 바이오 리미티드 펩타이드 백신
CA3110760A1 (en) 2018-09-04 2020-03-12 Treos Bio Limited Peptide vaccines
GB201814362D0 (en) 2018-09-04 2018-10-17 Treos Bio Zrt Composition and process for preparing vaccine
US11945850B2 (en) * 2018-09-17 2024-04-02 Immatics Biotechnologies Gmbh B*44 restricted peptides for use in immunotherapy against cancers and related methods
US12331320B2 (en) 2018-10-10 2025-06-17 The Research Foundation For The State University Of New York Genome edited cancer cell vaccines
TW202039535A (zh) 2018-12-18 2020-11-01 德商英麥提克生物技術股份有限公司 B*08限制肽和肽組合物抗癌免疫治療和相關方法
EP4100051A2 (en) * 2020-02-07 2022-12-14 ISA Pharmaceuticals B.V. Treatment of hpv-related diseases
KR102159921B1 (ko) * 2020-03-24 2020-09-25 주식회사 테라젠바이오 펩타이드 서열 및 hla 대립유전자 서열을 이용하여 신생항원을 예측하는 방법 및 컴퓨터 프로그램
GB202004974D0 (en) 2020-04-03 2020-05-20 Treos Bio Ltd Coronavirus vaccine
CN115715199A (zh) 2020-04-03 2023-02-24 帕普泰克疫苗有限公司 冠状病毒疫苗
EP4139923A1 (en) * 2020-04-20 2023-03-01 NEC Laboratories Europe GmbH A method and a system for optimal vaccine design
CN112048001B (zh) * 2020-09-08 2022-04-05 南方科技大学 一种肿瘤新生抗原多肽及其应用
KR102278727B1 (ko) * 2020-09-16 2021-07-19 주식회사 테라젠바이오 대상 암 조직 및 세포 유리형 dna 유래 펩타이드 서열 및 hla 클래스 ii 대립유전자 서열을 이용하여 신생항원을 예측하는 방법 및 컴퓨터 프로그램
US20240424094A1 (en) * 2021-10-06 2024-12-26 CancerVAX Inc. Methods and compositions for cancer treatment
EP4516932A1 (en) * 2022-04-27 2025-03-05 POSTECH Research and Business Development Foundation Method for constructing hotspot-derived peptide-nucleic acid hybrid molecules on basis of in vitro selection
CN115785203B (zh) * 2022-06-10 2024-03-12 河北博海生物工程开发有限公司 肺癌特异性分子靶标10及其用途
GB202216453D0 (en) 2022-11-04 2022-12-21 Lisziewicz Julianna Identification of antigens which induce t-cell responses

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100074925A1 (en) * 2006-09-21 2010-03-25 Vaxil Biotherapeutics Ltd Antigen specific multi epitope vaccines
JP2016506907A (ja) * 2013-01-15 2016-03-07 メモリアル スローン−ケタリング キャンサー センター 免疫原性ｗｔ−１ペプチドおよびその使用法
US20170032082A1 (en) * 2015-10-12 2017-02-02 Nantomics, Llc Systems, Compositions, And Methods For Discovery Of MSI And Neoepitopes That Predict Sensitivity To Checkpoint Inhibitors
US20170039314A1 (en) * 2010-03-23 2017-02-09 Iogenetics, Llc Bioinformatic processes for determination of peptide binding
JP2018508181A (ja) * 2014-12-09 2018-03-29 オンコセラピー・サイエンス株式会社 Ｔｈ１細胞のためのＧＰＣ３エピトープペプチドおよびこれを含有するワクチン

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235877A (en) 1979-06-27 1980-11-25 Merck & Co., Inc. Liposome particle containing viral or bacterial antigenic subunit
ATE511849T1 (de) 1996-03-11 2011-06-15 Epimmune Inc Peptide mit erhöhter bindungsaffinität für mindestens drei hla-a3-ähnliche moleküle
US6617434B1 (en) * 1996-05-31 2003-09-09 North Shore Long Island Jewish Research Institute Identificiaton of differentially methylated and mutated nucleic acids
US20030148463A1 (en) 1997-04-14 2003-08-07 Micromet Ag Novel method for the production of anti-human antigen receptors and uses thereof
ATE200679T1 (de) * 1997-04-14 2001-05-15 Micromet Ag Neues verfahren zur herstellung von anti-humanen antigenrezeptoren und deren verwendungen
FR2791895B1 (fr) 1999-03-23 2001-06-15 Pasteur Merieux Serums Vacc Utilisation de trehalose pour stabiliser un vaccin liquide
AUPQ776100A0 (en) 2000-05-26 2000-06-15 Australian National University, The Synthetic molecules and uses therefor
US6673580B2 (en) 2000-10-27 2004-01-06 Genentech, Inc. Identification and modification of immunodominant epitopes in polypeptides
US7892559B2 (en) 2002-01-30 2011-02-22 Survac Aps Survivin-derived peptides and use thereof
MXPA05002455A (es) 2002-09-06 2005-06-03 Mannkind Corp Secuencias de epitopes.
GB0228900D0 (en) * 2002-12-11 2003-01-15 Ml Lab Plc Cancer Immunotherapy
NZ543467A (en) 2003-04-10 2008-07-31 Novartis Vaccines & Diagnostic The severe acute respiratory syndrome coronavirus
US20050084913A1 (en) * 2003-04-22 2005-04-21 Maxygen, Inc. Novel tumor-associated antigens
US20050100883A1 (en) 2003-11-12 2005-05-12 Wang Chang Y. Peptide-based diagnostic reagents for SARS
WO2005068632A1 (ja) * 2004-01-20 2005-07-28 Aichi Prefecture ＨＬＡ−Ａ２４０２拘束性Ｅｐ−ＣＡＭ特異的ＣＴＬが認識するエピトープ・ペプチド及びその用途
JP2008509654A (ja) 2004-06-01 2008-04-03 イノジェネティックス・ナムローゼ・フェンノートシャップ Ｃ型肝炎ウイルスに対するｃｔｌおよび／またはｈｔｌ応答を誘導するためのペプチド
WO2006080142A1 (ja) 2005-01-25 2006-08-03 Nec Corporation Ｈｌａ結合性ペプチド、それをコードするｄｎａ断片および組み換えベクター
ES2523172T3 (es) 2005-02-04 2014-11-21 Survac Aps Vacuna de péptido de survivina
CN100402554C (zh) * 2005-02-25 2008-07-16 李玉新 睾丸特异性蛋白50人源抗体的制备及用途
FR2891462B1 (fr) 2005-09-30 2009-10-16 Commissariat Energie Atomique Epitopes t cd4+ de la survivine et leurs applications
GB0520067D0 (en) 2005-10-01 2005-11-09 Cancer Rec Tech Ltd Treatment of cancer
EP2084267B1 (en) 2006-09-26 2018-04-11 Cedars-Sinai Medical Center Cancer stem cell antigen vaccines and methods
EP2155782A2 (en) 2007-03-26 2010-02-24 Dako Denmark A/S Mhc peptide complexes and uses thereof in infectious diseases
EP2042600A1 (en) 2007-09-28 2009-04-01 Commissariat A L'energie Atomique A public and immunogenic CD4+ T Cell epitope of the hiv tat protein and its applications
JP5546448B2 (ja) 2008-03-31 2014-07-09 株式会社バイオイミュランス ＭＨＣクラスＩＩ分子に提示されるサーバイビン（Ｓｕｒｖｉｖｉｎ）の部分ペプチドとその利用法
ES2532896T5 (es) 2008-05-14 2018-03-20 Immatics Biotechnologies Gmbh Péptidos del MHC de clase II novedosos y potentes derivados de survivina y neurocan
TW201008574A (en) 2008-08-19 2010-03-01 Oncotherapy Science Inc INHBB epitope peptides and vaccines containing the same
EP2337795A2 (en) 2008-10-01 2011-06-29 Dako Denmark A/S Mhc multimers in cancer vaccines and immune monitoring
GB0818065D0 (en) * 2008-10-02 2008-11-05 Cancer Rec Tech Ltd Immunogenic peptides and uses thereof
US20120244145A1 (en) * 2009-11-16 2012-09-27 Duke University Enhanced immunological responses
GB201004575D0 (en) * 2010-03-19 2010-05-05 Immatics Biotechnologies Gmbh Composition of tumor associated peptides and related anti cancer vaccine for the treatment of gastric cancer and other cancers
WO2012051282A2 (en) * 2010-10-14 2012-04-19 The Ohio State University Research Foundation Piwil2-like (pl2l) proteins-targeted cancer diagnosis and therapy
EP2745845A1 (en) * 2012-12-19 2014-06-25 Centre Hospitalier Universitaire de Bordeaux A method for preventing or treating an HIV infection
WO2014180490A1 (en) * 2013-05-10 2014-11-13 Biontech Ag Predicting immunogenicity of t cell epitopes
GB201315946D0 (en) 2013-09-06 2013-10-23 Immune Targeting Systems Its Ltd Oncology vaccine
EP4461372A3 (en) * 2013-11-05 2025-01-22 Cognate Bioservices, Inc. Combinations of checkpoint inhibitors and therapeutics to treat cancer
WO2015143335A1 (en) 2014-03-20 2015-09-24 The University Of North Carolina At Chapel Hill Methods and compositions for chimeric coronavirus spike proteins
US10111948B2 (en) 2014-04-25 2018-10-30 Tria Bioscience Corp. Synthetic hapten carrier compositions and methods
CA2961179A1 (en) * 2014-09-14 2016-03-17 Washington University Personalized cancer vaccines and methods therefor
WO2016090177A1 (en) * 2014-12-03 2016-06-09 Verik Bio, Inc. Identification, selection and use of high curative potential t cell epitopes
RU2719033C2 (ru) * 2015-04-23 2020-04-16 Нантомикс, Ллс Способ получения фармацевтического агента для иммунотерапии рака
US11090332B2 (en) 2015-05-21 2021-08-17 Regen BioPharma, Inc. Antigen specific mRNA cellular cancer vaccines
GB201604755D0 (en) 2016-03-21 2016-05-04 Vaxeal Res Sas Immunogenic compositions
CN110352067B (zh) 2016-10-07 2024-09-24 得克萨斯州大学系统董事会 Hla限制性vgll1肽及其用途
WO2018138257A1 (en) 2017-01-27 2018-08-02 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
EP3370065A1 (en) 2017-03-03 2018-09-05 Treos Bio Kft Immunogenic peptides
KR20240156643A (ko) 2017-03-03 2024-10-30 트레오스 바이오 리미티드 펩타이드 백신
EP3369431A1 (en) 2017-03-03 2018-09-05 Treos Bio Kft Vaccine
AU2018395397A1 (en) 2017-12-28 2020-08-06 Gritstone Bio, Inc. Antigen-binding proteins targeting shared antigens
JP2021526365A (ja) 2018-05-18 2021-10-07 チルドレンズ ナショナル メディカル センターＣｈｉｌｄｒｅｎ’Ｓ Ｎａｔｉｏｎａｌ Ｍｅｄｉｃａｌ Ｃｅｎｔｅｒ 改善された標的化ｔ細胞療法
WO2019222762A1 (en) 2018-05-18 2019-11-21 Children's National Medical Center Improved cell therapy compositions for hematopoietic stem cell transplant patients
GB201814362D0 (en) 2018-09-04 2018-10-17 Treos Bio Zrt Composition and process for preparing vaccine
GB201814361D0 (en) 2018-09-04 2018-10-17 Treos Bio Zrt Immunogenetic cancer screening test
CA3110760A1 (en) 2018-09-04 2020-03-12 Treos Bio Limited Peptide vaccines
EP3908292A4 (en) 2019-01-07 2023-01-04 Children's National Medical Center IMPROVED TARGETED T-CELL THERAPY FOR THE TREATMENT OF MULTIPLE MYELOMA
US20220064598A1 (en) 2019-01-07 2022-03-03 Children's National Medical Center Ex vivo activated t-lymphocytic compositions and methods of using the same
GB202004974D0 (en) 2020-04-03 2020-05-20 Treos Bio Ltd Coronavirus vaccine

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100074925A1 (en) * 2006-09-21 2010-03-25 Vaxil Biotherapeutics Ltd Antigen specific multi epitope vaccines
US20170039314A1 (en) * 2010-03-23 2017-02-09 Iogenetics, Llc Bioinformatic processes for determination of peptide binding
JP2016506907A (ja) * 2013-01-15 2016-03-07 メモリアル スローン−ケタリング キャンサー センター 免疫原性ｗｔ−１ペプチドおよびその使用法
JP2018508181A (ja) * 2014-12-09 2018-03-29 オンコセラピー・サイエンス株式会社 Ｔｈ１細胞のためのＧＰＣ３エピトープペプチドおよびこれを含有するワクチン
US20170032082A1 (en) * 2015-10-12 2017-02-02 Nantomics, Llc Systems, Compositions, And Methods For Discovery Of MSI And Neoepitopes That Predict Sensitivity To Checkpoint Inhibitors

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BLOOD, 2014, VOL.124, NO.3, PP.453-462, JPN6022007533, ISSN: 0005229313 *
EXPERIMENTAL AND THERAPEUTIC MEDICINE, 2011, VOL.2, PP.109-117, JPN6022007531, ISSN: 0005229314 *

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20210086611A (ko) * 2018-09-04 2021-07-08 트레오스 바이오 리미티드 면역유전적 암 스크리닝 검사
JP2022500630A (ja) * 2018-09-04 2022-01-04 トレオス バイオ リミテッド 免疫原性がん検診検査
JP7419351B2 (ja) 2018-09-04 2024-01-22 トレオス バイオ リミテッド 免疫原性がん検診検査
KR102746607B1 (ko) 2018-09-04 2024-12-23 트레오스 바이오 리미티드 면역유전적 암 스크리닝 검사
WO2023017768A1 (ja) 2021-08-10 2023-02-16 日本電気株式会社 情報処理システム及び情報処理方法
WO2023058625A1 (ja) 2021-10-04 2023-04-13 日本電気株式会社 管理方法、管理システム及び電子カルテシステム
WO2024038510A1 (ja) 2022-08-17 2024-02-22 日本電気株式会社 情報処理システム、情報処理方法及びプログラム

Also Published As

Publication number Publication date
KR102591136B1 (ko) 2023-10-17
CL2019002532A1 (es) 2020-02-07
IL268917B2 (en) 2023-04-01
BR112019018307A2 (pt) 2020-03-31
CA3054871A1 (en) 2018-09-07
AU2018228786B2 (en) 2025-03-06
CO2019010524A2 (es) 2020-01-17
US20190240302A1 (en) 2019-08-08
CN110651189B (zh) 2024-10-25
MA47677A (fr) 2020-01-08
US11213578B2 (en) 2022-01-04
IL268920B2 (en) 2025-05-01
KR20240156643A (ko) 2024-10-30
KR102549625B1 (ko) 2023-06-28
IL268917B (en) 2022-12-01
CO2019010698A2 (es) 2020-01-17
MA47683A (fr) 2020-01-08
EP3589954A1 (en) 2020-01-08
SG11201906765UA (en) 2019-08-27
MA47678A (fr) 2021-05-26
EP3589951A1 (en) 2020-01-08
US11628211B2 (en) 2023-04-18
IL268919B1 (en) 2023-06-01
US20220111025A1 (en) 2022-04-14
CA3054861A1 (en) 2018-09-07
KR102723248B1 (ko) 2024-10-29
JP2020511672A (ja) 2020-04-16
IL268919A (en) 2019-10-31
US20220111024A1 (en) 2022-04-14
CN110651188A (zh) 2020-01-03
CO2019010503A2 (es) 2020-01-17
US20220072114A1 (en) 2022-03-10
US11426452B2 (en) 2022-08-30
JP7437939B2 (ja) 2024-02-26
CN119371510A (zh) 2025-01-28
IL268920B1 (en) 2025-01-01
AU2018228785A1 (en) 2019-08-01
CN110651188B (zh) 2024-02-02
US20180264094A1 (en) 2018-09-20
CL2022002836A1 (es) 2023-06-16
CA3054866A1 (en) 2018-09-07
MX2019010461A (es) 2020-01-09
ZA201904723B (en) 2024-01-31
SG11201907524UA (en) 2019-09-27
BR112019018313A2 (pt) 2020-05-19
US20180264095A1 (en) 2018-09-20
CN110651189A (zh) 2020-01-03
KR20190133177A (ko) 2019-12-02
ZA201904725B (en) 2024-01-31
US20220031823A1 (en) 2022-02-03
WO2018158455A1 (en) 2018-09-07
BR112019018312A2 (pt) 2020-03-31
US10213497B2 (en) 2019-02-26
AU2018226566B2 (en) 2025-01-23
EP3589310A1 (en) 2020-01-08
JP2023051941A (ja) 2023-04-11
IL268917A (en) 2019-10-31
JP2020514413A (ja) 2020-05-21
CL2019002533A1 (es) 2020-02-07
IL268920A (en) 2019-10-31
MX2019010459A (es) 2020-01-09
WO2018158457A1 (en) 2018-09-07
SG11201907402SA (en) 2019-09-27
AU2018226566A1 (en) 2019-08-01
AU2018228786A1 (en) 2019-08-01
CL2019002534A1 (es) 2020-02-07
WO2018158456A1 (en) 2018-09-07
AU2018228785B2 (en) 2024-09-26
US20180250399A1 (en) 2018-09-06
IL268919B2 (en) 2023-10-01
MX2019010460A (es) 2020-01-09
KR20190133010A (ko) 2019-11-29
JP7751374B2 (ja) 2025-10-08
KR20190134636A (ko) 2019-12-04
US20230405100A1 (en) 2023-12-21
CN110621334A (zh) 2019-12-27

Similar Documents

Publication Publication Date Title
JP7437939B2 (ja) 集団に基づいた免疫原性ペプチドの同定のプラットフォーム
JP2025069437A (ja) ワクチン組成物を調製するためのプロセス
JP2024097033A (ja) ペプチドワクチン
EA045699B1 (ru) Персонализированная платформа для идентификации иммуногенного пептида
EA045702B1 (ru) Платформа для идентификации иммуногенных пептидов популяционного уровня
EA048432B1 (ru) Вакцина

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210301

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210301

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20210326

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20210326

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220301

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220601

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20221018

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230117

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230320

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230620

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231020

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20231201

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20240105

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251125